Purpose: Nuclear receptor coactivator expression and activity may partly explain the complex agonist/ antagonist effects of tamoxifen at clinical level. In a preoperative trial, dose reduction from 20 to 1 mg tamoxifen was associated with retained antiproliferative effect on breast cancer. Here, we assessed the gene expression of the steroid receptor coactivators SRC-1, SRC-2/transcription intermediary factor 2, and SRC-3/amplified in breast cancer 1 (AIB1) and the growth factor receptor HER-2/neu under three tamoxifen dose regimens.
It is well established that estrogens contribute to carcinogenesis and cancer progression in estrogen receptor (ER)-positive breast cancer. Treatment with the selective ER modulator tamoxifen decreases mortality and lengthens disease-free survival in women with early ER-positive breast cancer (1) , and reduces the incidence of ER-positive breast cancer in women at increased risk (2) . Tamoxifen can act as an ER antagonist or agonist in which estrogenagonistic effects are associated with favorable effects such as prevention of bone fractures as well as detrimental effects, including an increased risk of endometrial cancer and venous thromboembolic events. The development of resistance to tamoxifen over time can further limit the use of tamoxifen in clinical practice.
The molecular target for tamoxifen therapy, the ER, belongs to the family of nuclear receptors that function as transcription factors. ER activity is regulated by the steroid receptor coactivators (SRCs) SRC-1, SRC-2/transcription intermediary factor 2 (TIF-2), and SRC-3/amplified in breast cancer 1 (AIB1), among others. The SRCs are genetically distinct but have similar functional and structural properties (3) . The coactivators recruit the general transcription machinery and are important modulators of transcription, involved in every step from chromatin remodeling to transcription termination, thereby facilitating ER-mediated gene transcription (3, 4) .
The coactivator SRC-3/AIB1 may play an important role in breast cancer resistance to tamoxifen therapy (5) .
Dissociation of SRC-3/AIB1 from ER inhibits breast cancer cell growth (6, 7) and restores tamoxifen sensitivity in resistant breast cancer cells (8) . Overexpression of SRC-3/ AIB1 increases the agonist properties of tamoxifen (9) and tamoxifen resistance develops when SRC-3/AIB1 is high and the transcriptional repressor paired box 2 (PAX2) is low in breast cancer cells (10) . SRC-3/AIB1 is considered as an oncogene leading to mammary hypertrophy, hyperplasia, and breast cancer development (11) (12) (13) . Overexpression of SRC-3/AIB1 has been found in 31% to 64% of human breast tumors and gene amplification in 2% to 10% (14) (15) (16) (17) . SRC-3/AIB1 levels are higher in breast carcinomas with high tumor grade (18) and increased SRC-3/AIB1 levels correlate with shorter disease-free survival (19) . The role of other SRCs in breast cancer development is less known. SRC-1 has been shown to contribute to the agonistic properties of 4-hydroxytamoxifen on ER (20) (21) (22) (23) (24) , and a study based on tissue microarray data has suggested that SRC-1 is a prognostic factor of reduced disease-free survival, also in tamoxifentreated breast cancers (25) . Recently, we have reported that SRC-1 and the human epidermal growth factor HER-2/neu are upregulated in vivo during estrogen deprivation using aromatase inhibitors (26) .
A functional relationship between SRCs and the HER family of receptors has been shown. SRC-3/AIB1 is important for HER-2/neu-induced tumorigenesis. In addition, increased signaling through HER-2/neu may stimulate coactivator function in breast cancer cells and thereby enhance the agonistic properties of tamoxifen (27) . Overexpression of HER-2/neu is associated with poor prognosis and tamoxifen resistance when overexpressed together with SRC-3/AIB1 (28) , and high levels of SRC-1 in HER-2/neu-positive patients have been linked to reduced disease-free survival (29) . Overall, the levels of coactivators and HER-2/neu have been pointed out to be the important determinants of tamoxifen effects (20, 30) underlining the importance of studying the regulation of coactivator and HER-2/neu expression in breast tumor tissue under endocrine treatment.
Tamoxifen is an antecedent of molecular targeted therapy whose minimal effective dose has not been defined. We have previously focused on tamoxifen dose reduction as a potential strategy to retain activity while reducing toxicity. In a preoperative randomized clinical trial using three different dose regimens of tamoxifen, we observed that a dose of either 5 or 1 mg/d of tamoxifen was associated with retained antitumor effect compared with the standard daily dose of 20 mg, as indicated by a similar reduction in the proliferation marker Ki67 (31) . In the present study, we examined whether tamoxifen treatment results in changes in mRNA expression of SRCs and HER-2/neu and whether potential changes are influenced by tamoxifen dose or tissue type, i.e., normal versus malignant breast tissue. As secondary targets, we investigated any potential correlation between gene expression and the breast cancer biomarkers insulin-like growth factor I (IGF-I), sex hormone binding globulin (SHBG), and Ki67. We also explored the potential prognostic value of the coactivators and HER-2/neu mRNA on clinical outcome and their relation to other prognostic factors. Our findings may provide insight into the regulatory mechanisms of breast cancer growth and the early response to an ER-blocking agent in both normal and malignant breast tissue, and offer clues to ameliorate the therapeutic index of tamoxifen.
Materials and Methods
Study design. The basis for this study was a previously randomized, double-blind, parallel trial with three arms investigating the effect of three different dose regimens of tamoxifen on the change in biomarkers associated with breast cancer proliferation and tamoxifen toxicity (31) . In short, 120 women with ER-positive breast cancer were randomly assigned after diagnostic biopsy to treatment with 1, 5, or 20 mg tamoxifen per day for 4 wk preoperatively. The subjects included had tumors <5 cm in diameter and had no evidence of distant metastasis. Both premenopausal and postmenopausal women were included. A total of 64 tumor specimens sampled at the time of surgery from tamoxifen-treated subjects were available for gene expression analysis. For 52 tamoxifen-treated subjects, we also had specimens from adjacent normal breast tissue. The nonrandomized nontreated group consisted of women who would otherwise be eligible for the original study (31) but did not receive preoperative treatment with tamoxifen because of accrual completion. Neither tamoxifen-treated nor tamoxifen-nontreated patients received any other therapy preoperatively and they all underwent surgery after a
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Sample collection. A tru-cut biopsy was taken from the primary tumor at the time of diagnosis and used for immunohistochemical and H&E-stained pathologic evaluation. In addition, a tumor sample and adjacent normal breast tissue, defined as below 1 cm from the tumor tissue, were retrieved during surgery and stored at −80°C until used for gene expression analysis. Blood samples were taken both at the beginning and at the end of the 4-wk tamoxifen treatment and stored at −80°C until biomarker analysis.
mRNA extraction and quantitative real-time reverse transcription-PCR. Tissue biopsies of ∼10 mg were homogenized using an IKA Ultra-Turrax T8 (IKA) and mRNA was extracted on the MagNa Pure LC with the MagNa Pure LC mRNA Isolation kit II according to the manufacturer's instructions (Roche). Each sample of mRNA was reverse transcribed using the 1st Strand cDNA Synthesis kit for reverse transcription-PCR (Roche). Real-time PCR for the coactivators were done in duplicate on the LightCycler 3 using LightCycler FastStart DNA Master PLUS SYBR Green I (Roche), whereas analysis for HER-2/neu was done on the LightCycler480 using LightCycler480 Probes Master (Roche) and a specific Universal ProbeLibrary probe #67 in duplex with Universal ProbeLibrary Human TBP Gene Assay (Roche). The gene-specific primer sequences (Eurogentec and TIB Molbiol) were as follows: SRC-1 5′-aggcccagagccagtttac-3′ [sense (s)] and 5′-caggatctccgatttgatggtta-3′ [antisense (as)], SRC-2/TIF-2 5′-gagtaccaacacaggcacc-3′ (s) and 5′-aggttgctgacttattccgtag-3′ (as), SRC-3/AIB1 5′-gaccgcttttacttcaggcatt-3′ (s) and 5′-tgtgttaaccaggtcctcttgct-3′ (as), HER-2/neu 5′-tgctgtcctgttcaccactc-3′ (s) and 5′-tcatcctcatcatcttcacattg-3′ (as), TATA-box binding protein (TBP) 5′-tgcacaggagccaagagtgaa-3′ (s) and 5′-cacatcacagctccccacca-3′ (as), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 5′-accacagtccatgccatcac-3′ (s) and 5′-tccaccaccctgttgctgta-3′ (as).
External standard curves of serially diluted plasmid with known concentration were established for the coactivators, whereas the standard curve for HER-2/neu was made using serially diluted cDNA from a HER-2/neu-positive patient sample. Messenger RNA expression levels for each target gene were quantified based on these standard curves and calculated relative to the expression of the housekeeping gene TBP. We also measured the expression of the housekeeping gene GAPDH. However, we observed a >100-fold higher expression level of GAPDH mRNA compared with our target genes and the induction of GAPDH in breast cancer tissue compared with normal tissue. Thus, we considered GAPDH to be less suitable as reference gene in our study.
Measurements of biomarkers in blood and tissue and pathologic evaluation. The biochemical tests for circulating IGF-I and SHBG, and the analytic methods for immunohistochemistry of ER, progesterone receptor (PR), Ki67, and HER-2/neu expression have been described in detail elsewhere (31) . In short, IGF-I levels were measured by a chemiluminiscent immunometric assay (Nichols Institute Diagnostics) on a LIAISON instrument (Byk Sangtec Diagnostica). The AutoDELFIA SHBG kit from Wallac was used for serum measurements of SHBG. Immunohistochemistry was done on dewaxed and pretreated tumor sections that were incubated with mouse monoclonal antibody to ER, PR, or Ki67 (DAKO). The results were presented as a percentage of immunoreactive cells of the total number of invasive malignant cells in the core biopsies and as a percentage from ≥2,000 malignant cells in the surgical specimens. For HER-2/ neu, a rabbit polyclonal antibody (DAKO) was used and HER-2/neu expression was scored by two pathologists as follows: 0, no staining or faint membrane staining; 1+, faint or incomplete membrane staining in >10% of tumor cells; 2+, weak to moderate membrane staining in >10% of tumor cells; and 3+, intense circumferential membrane staining in >10% of tumor cells. Microinvasive breast cancer was diagnosed according to the tumor-node-metastasis classification and the criteria of Rosen and Obermann (32); tumor grade was assessed according to Elston and Ellis (33) ; and peritumoral vascular invasion was evaluated as recommended by Rosen and Obermann (32) .
Follow-up and clinical outcome. A dedicated database for all tamoxifen-treated patients who underwent breast surgery with a diagnosis of breast cancer was developed to collect all relevant clinical data including demographics, relevant personal history, surgical treatment, tumor histology, and follow-up data including disease recurrence. Disease-free survival was defined as time from randomization to the next breast cancer event, i.e., disease recurrence at local, regional, or distant site; a new contralateral breast cancer; or death.
Statistics. Differences between groups at baseline for descriptive characteristics of the population were investigated using nonparametric tests. Messenger RNA levels over treatment groups were analyzed by a repeated measures ANOVA model in which treatment and tissue type were set as fixed factors and patient effect as random. Mixed effect models were used to take into consideration correlation between cancer and normal tissue in the same patient. Orthogonal contrasts were used to compare the differences between treatment groups: nontreated versus any tamoxifen, 1 mg/d versus 5 or 20 mg/d, and 5 versus 20 mg/d. The correlation between mRNA levels of our target genes was investigated using Spearman's correlation. Furthermore, using the repeated measures ANOVA model, we evaluated whether SRC-1, SRC-2/TIF-2, SRC-3/AIB1, and HER-2/neu could potentially explain the biomarker variability of Ki67, IGF-I, and SHBG after 4 wk of treatment.
A Cox proportional hazards model was used to identify independent predictors of survival. Survival time was computed from randomization to the date of event occurrence. In event-free subjects, the observation time was recorded at the last follow-up. All patients alive at the last followup date were considered right censored. Curves for diseasefree survival in relation to SRC-3/AIB1 expression were derived from Kaplan-Meier estimates and compared using the log-rank test.
When using statistical models, log and square root transformations were used when necessary to achieve normality. Statistical analyses were done on the SAS statistical software version 9.0 (SAS Institute, Inc) and/or the SPSS software, version 14.0.2 (SPSS, Inc.). The level of statistical significance for all statistical analyses was set at P < 0.05.
Results
Subject and tumor characteristics. The study population consisted of both premenopausal and postmenopausal women from the age of 43 years with newly diagnosed ER-positive cancers. The subject and tumor characteristics of this subgroup were not significantly different from the original cohort. The nontreated controls had a slightly higher proportion of premenopausal subjects compared with the treatment groups, but no statistically significant differences between groups were found at baseline for the patient and tumor characteristics presented in Table 1 .
Coactivator and HER-2/neu mRNA expression levels in relation to tissue type. The coactivators SRC-1, SRC-2/TIF-2, and SRC-3/AIB1 were detectable in both normal and malignant breast tissue. They were significantly upregulated in malignant tissue compared with normal tissue (P < 0.001; Table 2 ). The expression level of SRC-3/AIB1 in tumor was the highest of the coactivators with a median expression of 1.66 (interquartile range, 0.82-2.74) relative to TBP. The expression of SRC-1 was comparable, but lower at 1.22 (0.84-2.04), and the median levels of SRC-1 and SRC-3/AIB1 were 4.6-to 6.3-fold higher than the median expression level of SRC-2/TIF-2 at 0.26 (0.16-0.49).
As for malignant tissue, SRC-3/AIB1 in normal tissue for the whole study population including tamoxifen-nontreated subjects showed the highest expression level of the coactivators with a median value of 1.31 (0.59-1.74), whereas SRC-2/ TIF-2 had the lowest mRNA level with a median of 0.13 (0.07-0.27). The expression levels of the coactivators were higher in the tumor tissue relative to the normal tissue for all treatment groups and for the nontreated group. In addition, a treatment effect with the upregulation of mRNA levels during tamoxifen treatment was observed in both normal and malignant breast tissue (Table 2 ; Fig. 1 ).
HER-2/neu mRNA expression was also significantly higher in tumor tissue, with a median of 0.51 (0.30-0.73) in malignant tissue compared with 0.39 (0.14-0.48) in normal tissue for the study population as a whole. Median values for HER-2/neu mRNA were consistently higher in tumor compared with normal tissue for the individual treatment groups and for nontreated subjects.
Coactivator and HER-2/neu mRNA expression levels in relation to tamoxifen treatment and dose. After 4 weeks of preoperative treatment with tamoxifen, we found higher expression levels for SRC-1, SRC-2/TIF-2, and SRC-3/ AIB1 in tamoxifen-treated compared with nontreated patients (Fig. 1) . For SRC-3/AIB1, the difference in mRNA levels in tumor was highly significant (P < 0.001) when comparing tamoxifen-treated with nontreated subjects, and the difference was also significant for SRC-1 (P = 0.002) and SRC-2/TIF-2 (P = 0.009). SRC-3/AIB1 mRNA was positively correlated with SRC-1 (P = 0.007), but not with SRC-2/TIF-2.
We found no significant changes in HER-2/neu mRNA expression between tamoxifen-treated and nontreated tissue but the expression levels in the tumors tended to be lower after tamoxifen treatment (P = 0.06). HER-2/neu mRNA levels were positively correlated with SRC-3/AIB1 mRNA (P = 0.016) but not with the other two coactivators.
When evaluating the effect of tamoxifen dose on coactivator expression, we found a clear induction of all three SRCs already in the lowest dose group receiving 1 mg tamoxifen daily (Table 2 ). It is noteworthy that there was no significant difference in SRC-1, SRC-2/TIF-2, or SRC-3/ AIB1 mRNA expression between the three doses. When we compared the treatment groups receiving 1 mg versus 5 or 20 mg, and 5 versus 20 mg tamoxifen, no significant differences in coactivator mRNA levels could be seen neither in normal nor tumor tissue (Table 2) .
Coactivator and HER-2/neu mRNA expression levels in relation to blood and tissue biomarkers. As reported previously (31), the levels of IGF-I decreased and SHBG increased in a dose-dependent manner during tamoxifen treatment, whereas the levels of the proliferation marker Ki67 declined to the same extent in all three dose groups compared with the nontreated group. These trends were observed also in the subgroup of patients for which we could evaluate the association with coactivators (Table 3) . However, we found that neither the coactivators nor HER-2/neu Abbreviations: q1, quartile 1; q3, quartile 3; tam, tamoxifen. *P values from a random effects model, taking into account correlations within subjects and using orthogonal contrasts to compare differences in coactivator levels between treatment groups and tissue types.
mRNA could significantly explain the variability of Ki67, IGF-I, or SHBG after 4 weeks of tamoxifen treatment, although the results for SRC-1 and Ki67 bordered on significance with P = 0.08 (Table 3) .
HER-2/neu overexpression at immunohistochemistry, defined as having an HER-2/neu score of 3, was verified in 17 of 92 tumors (18%). In nontreated subjects, HER-2/ neu overexpression was associated with the higher expression level of HER-2/neu mRNA, with a median of 1.70 versus 0.76 for subjects with a HER-2/neu score of 0 to 2. No significant difference in HER-2/neu mRNA levels in relation to the HER-2/neu score was observed for tamoxifen-treated subjects (Table 4) . It should be noted, however, that in tamoxifen-treated subjects, information on HER-2/ neu immunohistochemistry was collected at diagnosis and information on mRNA levels was collected at surgery, with a 4-week period of tamoxifen treatment in between.
Coactivator and HER-2/neu mRNA expression levels in relation to clinical outcome and prognostic markers in tamoxifen-treated subjects. After a median follow-up time of 8 years, five deaths were recorded and 16 subjects had a disease recurrence. In a Cox model of disease-free survival, neither the coactivators nor HER-2/neu mRNA levels at surgery had prognostic significance, whereas a Ki67 level of ≥20% at surgery was prognostic with a hazard ratio of 3.13 (95% confidence interval, 1.17-8.40; P = 0.02).
Due to the low number of observations, the data on coactivators and HER-2/neu mRNA levels in relation to clinical outcome and prognostic markers did not reach statistical significance and the results must be interpreted with caution. SRC-3/AIB1 expression tended to be higher in the tumors with Ki67 levels of ≥20% at biopsy (P = 0.07) and in tumors with unfavorable prognostic markers at surgery (Ki67, perivascular invasion; Table 4 ; Fig. 2A ). There was also a trend for median SRC-3/AIB1 levels to be higher in the groups with poor clinical outcome ( Fig. 2A) . Further, curves of disease-free survival derived from Kaplan-Meier estimates showed a tendency toward improved survival in the quartile with the lowest expression levels of SRC-3/ AIB1 after 4 weeks of neoadjuvant tamoxifen (P = 0.05 by log-rank test; Fig. 2B ).
Discussion
The expression of nuclear receptor coactivators may be of importance to the balance between estrogen agonistic and antagonistic effects of tamoxifen and has been shown to influence tumor responsiveness and the adverse effects of endocrine therapy (20, (28) (29) (30) 34) . In the present study, we observed an induction of the mRNA expression levels of SRCs during tamoxifen treatment with higher expression levels observed in malignant tissue compared with normal tissue. Interestingly, the inductive effect of tamoxifen on mRNA levels was observed in both tissue types. SRC-3/AIB1 had the highest expression level in tumors and most clearly showed the treatment effect on coactivator expression in both normal and malignant tissue. The coactivators were induced by tamoxifen with no difference in effect between the doses of 1, 5, and 20 mg of tamoxifen, which is in line with a previous observation on Ki67 (31) . Fig. 1 . Gene expression of the nuclear receptor coactivators SRC-1, SRC-2/TIF-2, and SRC-3/AIB1 in relation to tamoxifen dose and tissue type. Tumor and adjacent normal breast tissue specimens were collected at surgery after 4 wk of preoperative tamoxifen treatment. Messenger RNA expression levels were analyzed by real-time reverse transcription-PCR, calculated relative to the housekeeping gene TBP, and are presented as geometric means with 95% confidence intervals. Differences in mRNA levels between nontreated and tamoxifen-treated subjects were analyzed using a random effects model, with P < 0.001 in normal tissue and P < 0.01 in cancer tissue for all three coactivators.
The present results on the upregulation of SRC-3/AIB1 mRNA expression after tamoxifen treatment are supported by previous studies in breast cancer cell lines (35) . The potential roles of SRC-1 and SRC-2 in breast cancer development are less described (25) . In the clinical setting, high levels of SRC-1 and/or SRC-3/AIB1 are associated with poor response to tamoxifen and the development of endocrine resistance (28, 29) . By inducing the mRNA expression of ER coactivators, tamoxifen treatment may facilitate changes in gene expression, which could be interpreted as an attempt to shift the cell back to a more estrogen-sensitive state. Hence, the increase in coactivator levels may be interpreted as an early response to an ERantagonist in which we observed no significant difference in coactivator induction between low-dose and standarddose tamoxifen.
Additional steps facilitating posttranslational modifications of the coactivators could lead to increased coactivator activity and mediate a shift toward ER-agonistic effects of tamoxifen, also in breast cancer cells, ultimately contributing to tamoxifen resistance to develop over time (20, 36) . The coactivators and ER have been shown to interact with growth factor receptor pathways, which can contribute to cancer cell proliferation and invasion in the absence of estrogen (21, (36) (37) (38) (39) . For instance, phosphorylation by phosphoinositide 3-kinase (PI3K) and the mitogen-activated protein kinases, which are found downstream of growth factor receptors such as IGF-IR and HER-2/neu, can relocate, stabilize, and functionally activate the coactivators and lead to increased ER activity (40) (41) (42) (43) . Interestingly, targeting growth factor pathways such as the PI3K/Akt and mitogen-activated protein kinase signaling with wortmannin or tyrosine kinase inhibitors can partly restore endocrine sensitivity in cellular and animal models of endocrine-resistant breast cancer (42, 44) . These observations point toward potential therapeutic strategies targeting the cross-talk between ER and growth factor pathways in which the coactivators may play a pivotal role.
The relevance of interaction between growth factor pathways and SRCs is evident in tumors with high expression of HER-2/neu and SRC-3/AIB1, which are associated with tamoxifen resistance and poor patient outcome (28) . We did not observe any significant difference in the mRNA expression levels of HER-2/neu between tamoxifen-treated and nontreated subjects, which contrasts the clear induction of HER-2/neu mRNA expression we observed in breast tumor tissue after 13 to 16 weeks of neoadjuvant treatment with aromatase inhibitors (26) . It should be noted, however, that both estradiol and tamoxifen have been reported to decrease the HER-2/neu mRNA level in MCF-7 cells (10). The expression levels of SRC-3/AIB1 and HER-2/neu mRNA were significantly positively correlated in the present study, which is also in line with in vitro studies in which high levels of SRC-3/AIB1 have been shown to induce transcription of HER-2/neu after tamoxifen treatment by outcompeting the transcription factor PAX2 (10) . There is also evidence from animal models that SRC-3/AIB1 is required for the oncogenic effects of HER-2/neu by playing a significant role in (45) .
In this study, tamoxifen in the 1-to 20-mg dose range induced coactivator mRNA expression in a dose-independent manner, whereas serum and tissue levels of tamoxifen and metabolites would be influenced by tamoxifen dose (46) .
Further clinical studies on low-dose tamoxifen will be necessary to clarify issues about the role of nuclear receptor coactivators, tamoxifen metabolite profile, and response to endocrine treatment. Phase II and III clinical trials are under way to assess the efficacy of tamoxifen at 5 mg/d in different clinical conditions, including women with prior history of intraepithelial neoplasia or microinvasive disease (47) and women on postmenopausal hormone therapy (48) . We found Ki67 levels after 4 weeks of preoperative tamoxifen treatment to be a good prognosticator for clinical outcome, which is in line with previous studies (49) . Although we cannot conclude from this study due to the low number of subjects in the treatment arms, we did observe a trend in which mRNA levels of SRC-3/AIB1 were higher in the groups with poor clinical outcome and unfavorable prognostic factors. This fits well with the role of SRC-3/AIB1 as an oncogene, in which the coactivator has been shown to directly regulate the expression of cell cycle regulators such as cyclin D1 (6, 50) , and also facilitate migration and the metastatic behavior of cells, in part through the transcriptional regulation of matrix metalloproteinases and the activation of the PI3K/Akt/mammalian target of rapamycin pathway (11) (12) (13) .
The present study has some limitations. Treatment groups were small and results of exploratory analyses for several variables were evaluated. The P values presented have not been adjusted for multiple comparisons, and findings of borderline significance should be interpreted with caution.
Regarding the study design, it should be noted that the intervention period was only 4 weeks. Although drug concentrations may have reached steady state, the full effects on gene expression during long-term treatment with tamoxifen may not have become evident within this time frame. The control group was not randomized and was slightly different from the intervention groups for some characteristics. As a general comment, it is uncertain whether the surrounding normal tissue in a breast affected by breast cancer is indeed normal. Further, when interpreting the gene expression results from tumor tissue, it should be kept in mind that malignant tumors often are heterogenous and that gene expression patterns can be assumed to vary even within a single tumor. It is worth noting that changes in mRNA and protein expression and activity do not always go in parallel (5, 16) , partly due to other regulatory mechanisms such as posttranslational modifications and protein degradation.
In summary, we have observed that tamoxifen treatment upregulates the mRNA expression level of SRCs, especially SRC-3/AIB1, in both normal and malignant tissue with equal potency at doses as low as 1 mg compared with the standard daily dose of 20 mg. Further trials of A, median SRC-3/AIB1 expression with error bars indicating interquartile range. Ki67 was measured by immunohistochemistry at diagnostic biopsy and at surgery after 4 wk of tamoxifen treatment. The cutoff for high proliferating tumors was set at Ki67 ≥ 20%. B, Kaplan-Meier curves for disease-free survival after a median follow-up time of 8 y, comparing subjects in the lower quartile (<1.5) to subjects with higher SRC-3/AIB1 mRNA expression levels (≥1.5). Indicated P value was obtained by log-rank test.
low-dose tamoxifen are warranted both in breast cancer treatment and prevention setting, and the issues of nuclear receptor coactivators, tamoxifen metabolite profile, and treatment response should be further explored.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
